Imaging in clinical trials.

Abstract

Imaging is likely to play an increasingly important role in clinical trials of antirheumatic drugs. The need to evaluate efficacy of a drug quickly often precludes the use of radiological evaluation as an outcome measure, particularly in chronic arthritides. New imaging techniques with the refinement to detect differential early change, often between drugs of comparable potency, would be advantageous. However, the trend to set up large scale multicentre trials that have adequate statistical power for the detection of change mitigates against the use of expensive imaging techniques of restricted access. The majority of drug trials, therefore, still resort to conventional radiology. With the new generation of drugs that have specific actions, sensitivity in comparing changes in synovium, cartilage, bone and adjacent soft tissues would be of value.